Context: The pharmaceutical industry is among the largest investors in R&D worldwide, with leading companies spending up to USD 10 billion annually on R&D. However, it is becoming increasingly difficult for these companies to develop and gain approval for a number of new drugs that corresponds to their input (R&D expenditures). While some companies remain highly successful despite all challenges, others are finding it increasingly difficult to sustain a long-term business model that primarily focuses on innovation.
Scope: In this context, a new thesis project on the topic of "Product Life Cycle" is being offered. The study will specifically analyze the life cycles of new drugs approved approved by the FDA between 2000 and 2014, focusing on the following aspects: (i) Commercial success, (ii) drug modality, (iii) therapeutic area, (iv) internal vs. external source, and (v) regulatory approval path.
Goal: The goal is to develop a prototype life cycle (post-market launch) for new drugs and define subsegments based on the above-mentioned variables.
Your profile:
Contact and application: For further information or if you want to apply, please contact Prof. Dr. Naomi Häfner (naomi.haefner@unisg.ch) or Alexander Schuhmacher (alexander.schuhmacher@thi.de)
Note: The theses topics are available by February 2025
Ass. Prof.